Client Success
Our norms beat the industry by an improved rate of more than 50% in every major area of the clinical trial process. From enrollment, to speed and data quality, to the overall success rate, Numoda Technologies’ results speak for themselves.
| The results - Some metrics | |||
| Norms | Industry | NT | Improved |
| SUCCESS RATE: In Phase III Clinical Trials | 59%(1) (50% in oncology) | >90% | >53% |
| ENROLLMENT: Percent of invalid patients enrolled | 7.5% (EDC)-15%(paper)(2) | <1% | >86%-93% |
DATA QUALITY:
Queries/page of patient data | 1(3) | <0.4 | >60% |
SPEED:
Study database start-up Time needed to database lock after last patient data | 51.5 days(4) >65 days(3) | <21 days Hours | >62% >30X |
| (1) Lehman Brothers, 2006 “Late-Stage R&D Productivity: A Lehman Look at European Pharma R&D.” (2) Dr. Thomas Bart, “Comparison of Electronic Data Capture with Paper Data Collection,” Pharmwatch, 2003. (3) Kola and Landis, “Can the pharmaceutical industry reduce attrition rates?;” Nature Rev Drug Discovery. 3, 711-715 (2004); Practical Guide to Clinical Data Management, Second Edition, p. 66; INC Research. (4) Fitzmartin RD, Drug Information Journal 2001; 35:671-679 | |||
Our libraries of case histories are full of countless tales of trials rescued, such as these:
- Having failed two clinical trials based on data inconsistencies, a biopharma, after running a new trial with our services, was able to receive FDA approval which led them to $200MM in annual sales.
- A medical device company with 6,000 queries, 600 SAEs and a previous FDA failure was able to receive FDA approval in addition to $400MM deal with Johnson & Johnson after partnering with us.
- A biotech that had failed 50% of all its trials completed a successful trial and thereafter was able to secure $1.4 billion partnership with GlaxoSmithKline as a result of our partnership.
We pride ourselves on the successes of our clients.
No comments:
Post a Comment